Short Term Corticosteroids in SARS-CoV2 Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-04-01

Study Completion Date

2020-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators reviewed the charts of SARS-CoV-2 patients with pneumonia and moderate to severely elevated CRP and worsening hypoxemia who were treated with early, short-term dexamethasone.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Dexamethasone and COVID-19 Inpatient Mortality

NCT04926571

Coronavirus

COMPLETED

Comparing the Effects of Different Doses of Dexamethasone to Treat Inpatient COVID-19

NCT04707534

Covid19

COMPLETED PHASE4

Glucocorticoid Therapy in Coronavirus Disease COVID-19 Patients

NCT04780581

Corona Virus Infection

TERMINATED PHASE4

Impact of Steroids on Inflammatory Response in Covid-19

NCT04909918

Covid19

COMPLETED PHASE3

Randomized Clinical Trial of Intranasal Dexamethasone as an Adjuvant in Patients With COVID-19

NCT04513184

Covid19

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Corticosteroids Covid19 SARS-CoV 2 Steroids Dexamethasone

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SARS-CoV2 patients that received dexamethasone

Dexamethasone

Intervention Type DRUG

4mg dexamethasone was given to some patients three times daily for 2 days, 2 times daily for 2 days, once daily for 2 days.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dexamethasone

4mg dexamethasone was given to some patients three times daily for 2 days, 2 times daily for 2 days, once daily for 2 days.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Moderate disease with at least a 30% increase in CRP within 36 hours of admission, and with increasing oxygen requirements.
2. All patients with severe disease with evidence of escalating oxygen requirements
3. The presence of secondary bacterial infections as a probable cause of increasing CRP levels was excluded in all selected patients.
4. Pulmonary embolism and /or cardiac dysfunction were excluded as probable causes of worsening hypoxia in all selected patients.

Exclusion Criteria

1. All patients on other treatment modalities- Remdesivir and/or Convalescent plasma who showed evidence of clinical improvement as per decrease in CRP levels and/or oxygen requirements were excluded.
2. Patient with associated COPD exacerbation who would benefit from the use of steroids.
3. Patients with Diabetic ketoacidosis, hyperglycemic hyperosmolar state, active concurrent bacterial infections.
4. Patients with history of steroid-induced mania and/or psychosis.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes